On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide

Diabetes mellitus is a long-term chronic disease characterized by abnormal high level blood glucose (BG). An artificial closed-loop system that mimics pancreatic β-cells and releases insulin on demand has potential to improve the therapeutic efficiency of diabetes. Herein, a lectin Concanavalin A mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2022-12, Vol.352, p.673-684
Hauptverfasser: Bai, Jie, Zhang, Huijuan, Yang, Zhi, Li, Pinglan, Liu, Bin, Li, Dan, Liang, Shuang, Wang, Qimeng, Li, Zekun, Zhang, Jipeng, Chen, Shanan, Hou, Guohua, Li, Yuan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 684
container_issue
container_start_page 673
container_title Journal of controlled release
container_volume 352
creator Bai, Jie
Zhang, Huijuan
Yang, Zhi
Li, Pinglan
Liu, Bin
Li, Dan
Liang, Shuang
Wang, Qimeng
Li, Zekun
Zhang, Jipeng
Chen, Shanan
Hou, Guohua
Li, Yuan
description Diabetes mellitus is a long-term chronic disease characterized by abnormal high level blood glucose (BG). An artificial closed-loop system that mimics pancreatic β-cells and releases insulin on demand has potential to improve the therapeutic efficiency of diabetes. Herein, a lectin Concanavalin A modified oxidized starch nanogel was designed to regulate glucose dynamically according to different glucose concentrations. The nanogels were formed by double cross-linking the Concanavalin A and glucose units on oxidized starch via specific binding and amide bonds to achieve the high drug loading and glucose responsiveness. The results showed that oxidized starch nanogels prolonged the half-life of antidiabetic peptide drug exenatide and released it in response to high BG concentrations. It could absorb BG at a high level and maintain glucose homeostasis. Besides, the oxidized starch nanogels performed well in recovering regular BG level from hyperglycemia state and maintaining in euglycemia state that fitted in a biological rhythm. In addition, the nanogels showed high biocompatibility in vivo and could improve plasma half-life and therapeutic efficacy of exenatide. Overall, the nanogels protected peptide drugs from degradation in plasma as a glucose-responsive platform showing a high potential for peptide drugs delivery and antidiabetic therapy. A lectin Concanavalin A (Con A) modified oxidized starch (OS) nanogels was developed through inverse-emulsion method by double cross-linking via Con A-glucose unit specific affinity binding and amide bonds between Con A and carboxyl groups on the TEMPO-oxidized starch. Peptide drug exenatide (EX) with extremely short half-life was effectively loaded into the nanogels due to its excellent swelling capacity. The EX-loaded nanogels showed a glucose-responsive controlled release property and could maintain glucose homeostasis. At low glucose concentration, the nanogels showed an interesting swelling and deswelling behavior as an “on-off” effect in response to adding glucose and removing glucose in the media. However, at high glucose concentration, glucose could competitively bind to Con A on nanogels, disrupting the nanogels and releasing the loaded EX to adjust the blood glucose level. The EX-loaded nanogels with a high biocompatibility showed a long-term therapeutic effect in diabetic mice. [Display omitted] •OS-Con A Ngels were prepared by double cross-linking via affinity and amide bonds.•OS-Con A Ngels showed a high b
doi_str_mv 10.1016/j.jconrel.2022.10.039
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153842411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365922007179</els_id><sourcerecordid>2736303326</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-bfeefbaec6c8a99d9da8d9a18213680a0bafe27d968a14207e7ceaeccc31eae93</originalsourceid><addsrcrecordid>eNqFkc1qGzEUhUVoSNy0j9CiZTfj6mdGI61KMOkPBLJp1kIj3XFlNJIrzZikL9DXroydbrO6cPjOOXAPQh8oWVNCxefdemdTzBDWjDBWtTXh6gKtqOx50yrVvUGrysmGi05do7el7AghHW_7K3TNBe9b0YoV-vsQsYPJRIczbJdgZp8iTiMeQkoOb8NiUwEc4AABD8948MmmaV-xIQBOT975P-BwmU22v5pN9d7iaGLaQih4TPkloclQ9ikWf4BaFMDU0NoCTxBrloN36HI0ocD7871Bj1_vfm6-N_cP335sbu8by5Wcm2EEGAcDVlhplHLKGemUoZJRLiQxZDAjsN4pIQ1tGemht1BxazmtV_Eb9OmUu8_p9wJl1pMvFkIwEdJSNKcdly1rKX0VZX19I-GciYp2J9TmVEqGUe-zn0x-1pTo41x6p89z6eNcR7nOVX0fzxXLMIH773rZpwJfTkB9Jxw8ZF2sh2jB-Qx21i75Vyr-AcPmrQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2736303326</pqid></control><display><type>article</type><title>On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bai, Jie ; Zhang, Huijuan ; Yang, Zhi ; Li, Pinglan ; Liu, Bin ; Li, Dan ; Liang, Shuang ; Wang, Qimeng ; Li, Zekun ; Zhang, Jipeng ; Chen, Shanan ; Hou, Guohua ; Li, Yuan</creator><creatorcontrib>Bai, Jie ; Zhang, Huijuan ; Yang, Zhi ; Li, Pinglan ; Liu, Bin ; Li, Dan ; Liang, Shuang ; Wang, Qimeng ; Li, Zekun ; Zhang, Jipeng ; Chen, Shanan ; Hou, Guohua ; Li, Yuan</creatorcontrib><description>Diabetes mellitus is a long-term chronic disease characterized by abnormal high level blood glucose (BG). An artificial closed-loop system that mimics pancreatic β-cells and releases insulin on demand has potential to improve the therapeutic efficiency of diabetes. Herein, a lectin Concanavalin A modified oxidized starch nanogel was designed to regulate glucose dynamically according to different glucose concentrations. The nanogels were formed by double cross-linking the Concanavalin A and glucose units on oxidized starch via specific binding and amide bonds to achieve the high drug loading and glucose responsiveness. The results showed that oxidized starch nanogels prolonged the half-life of antidiabetic peptide drug exenatide and released it in response to high BG concentrations. It could absorb BG at a high level and maintain glucose homeostasis. Besides, the oxidized starch nanogels performed well in recovering regular BG level from hyperglycemia state and maintaining in euglycemia state that fitted in a biological rhythm. In addition, the nanogels showed high biocompatibility in vivo and could improve plasma half-life and therapeutic efficacy of exenatide. Overall, the nanogels protected peptide drugs from degradation in plasma as a glucose-responsive platform showing a high potential for peptide drugs delivery and antidiabetic therapy. A lectin Concanavalin A (Con A) modified oxidized starch (OS) nanogels was developed through inverse-emulsion method by double cross-linking via Con A-glucose unit specific affinity binding and amide bonds between Con A and carboxyl groups on the TEMPO-oxidized starch. Peptide drug exenatide (EX) with extremely short half-life was effectively loaded into the nanogels due to its excellent swelling capacity. The EX-loaded nanogels showed a glucose-responsive controlled release property and could maintain glucose homeostasis. At low glucose concentration, the nanogels showed an interesting swelling and deswelling behavior as an “on-off” effect in response to adding glucose and removing glucose in the media. However, at high glucose concentration, glucose could competitively bind to Con A on nanogels, disrupting the nanogels and releasing the loaded EX to adjust the blood glucose level. The EX-loaded nanogels with a high biocompatibility showed a long-term therapeutic effect in diabetic mice. [Display omitted] •OS-Con A Ngels were prepared by double cross-linking via affinity and amide bonds.•OS-Con A Ngels showed a high biocompatibility and glucose stimuli-responsive property.•OS-Con A Ngels could responsively release EX and regulate glucose hemostasis.•The Ngels prolonged the half-life of EX and improved the glucose regulating property.•Ngels-EX showed both short and long-term therapeutic efficacy in diabetes mice.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2022.10.039</identifier><identifier>PMID: 36374646</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antidiabetic therapy ; biocompatibility ; biological rhythms ; Blood Glucose ; Blood glucose homeostasis ; chronic diseases ; closed loop systems ; Concanavalin A ; crosslinking ; diabetes mellitus ; Drug Carriers - chemistry ; drugs ; Exenatide ; Glucose ; Glucose-responsive delivery ; half life ; homeostasis ; hyperglycemia ; Hypoglycemic Agents ; insulin ; Nanogels ; oxidation ; Oxidized starch nanogels ; peptides ; Starch ; therapeutics</subject><ispartof>Journal of controlled release, 2022-12, Vol.352, p.673-684</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-bfeefbaec6c8a99d9da8d9a18213680a0bafe27d968a14207e7ceaeccc31eae93</citedby><cites>FETCH-LOGICAL-c398t-bfeefbaec6c8a99d9da8d9a18213680a0bafe27d968a14207e7ceaeccc31eae93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365922007179$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36374646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Jie</creatorcontrib><creatorcontrib>Zhang, Huijuan</creatorcontrib><creatorcontrib>Yang, Zhi</creatorcontrib><creatorcontrib>Li, Pinglan</creatorcontrib><creatorcontrib>Liu, Bin</creatorcontrib><creatorcontrib>Li, Dan</creatorcontrib><creatorcontrib>Liang, Shuang</creatorcontrib><creatorcontrib>Wang, Qimeng</creatorcontrib><creatorcontrib>Li, Zekun</creatorcontrib><creatorcontrib>Zhang, Jipeng</creatorcontrib><creatorcontrib>Chen, Shanan</creatorcontrib><creatorcontrib>Hou, Guohua</creatorcontrib><creatorcontrib>Li, Yuan</creatorcontrib><title>On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Diabetes mellitus is a long-term chronic disease characterized by abnormal high level blood glucose (BG). An artificial closed-loop system that mimics pancreatic β-cells and releases insulin on demand has potential to improve the therapeutic efficiency of diabetes. Herein, a lectin Concanavalin A modified oxidized starch nanogel was designed to regulate glucose dynamically according to different glucose concentrations. The nanogels were formed by double cross-linking the Concanavalin A and glucose units on oxidized starch via specific binding and amide bonds to achieve the high drug loading and glucose responsiveness. The results showed that oxidized starch nanogels prolonged the half-life of antidiabetic peptide drug exenatide and released it in response to high BG concentrations. It could absorb BG at a high level and maintain glucose homeostasis. Besides, the oxidized starch nanogels performed well in recovering regular BG level from hyperglycemia state and maintaining in euglycemia state that fitted in a biological rhythm. In addition, the nanogels showed high biocompatibility in vivo and could improve plasma half-life and therapeutic efficacy of exenatide. Overall, the nanogels protected peptide drugs from degradation in plasma as a glucose-responsive platform showing a high potential for peptide drugs delivery and antidiabetic therapy. A lectin Concanavalin A (Con A) modified oxidized starch (OS) nanogels was developed through inverse-emulsion method by double cross-linking via Con A-glucose unit specific affinity binding and amide bonds between Con A and carboxyl groups on the TEMPO-oxidized starch. Peptide drug exenatide (EX) with extremely short half-life was effectively loaded into the nanogels due to its excellent swelling capacity. The EX-loaded nanogels showed a glucose-responsive controlled release property and could maintain glucose homeostasis. At low glucose concentration, the nanogels showed an interesting swelling and deswelling behavior as an “on-off” effect in response to adding glucose and removing glucose in the media. However, at high glucose concentration, glucose could competitively bind to Con A on nanogels, disrupting the nanogels and releasing the loaded EX to adjust the blood glucose level. The EX-loaded nanogels with a high biocompatibility showed a long-term therapeutic effect in diabetic mice. [Display omitted] •OS-Con A Ngels were prepared by double cross-linking via affinity and amide bonds.•OS-Con A Ngels showed a high biocompatibility and glucose stimuli-responsive property.•OS-Con A Ngels could responsively release EX and regulate glucose hemostasis.•The Ngels prolonged the half-life of EX and improved the glucose regulating property.•Ngels-EX showed both short and long-term therapeutic efficacy in diabetes mice.</description><subject>Antidiabetic therapy</subject><subject>biocompatibility</subject><subject>biological rhythms</subject><subject>Blood Glucose</subject><subject>Blood glucose homeostasis</subject><subject>chronic diseases</subject><subject>closed loop systems</subject><subject>Concanavalin A</subject><subject>crosslinking</subject><subject>diabetes mellitus</subject><subject>Drug Carriers - chemistry</subject><subject>drugs</subject><subject>Exenatide</subject><subject>Glucose</subject><subject>Glucose-responsive delivery</subject><subject>half life</subject><subject>homeostasis</subject><subject>hyperglycemia</subject><subject>Hypoglycemic Agents</subject><subject>insulin</subject><subject>Nanogels</subject><subject>oxidation</subject><subject>Oxidized starch nanogels</subject><subject>peptides</subject><subject>Starch</subject><subject>therapeutics</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1qGzEUhUVoSNy0j9CiZTfj6mdGI61KMOkPBLJp1kIj3XFlNJIrzZikL9DXroydbrO6cPjOOXAPQh8oWVNCxefdemdTzBDWjDBWtTXh6gKtqOx50yrVvUGrysmGi05do7el7AghHW_7K3TNBe9b0YoV-vsQsYPJRIczbJdgZp8iTiMeQkoOb8NiUwEc4AABD8948MmmaV-xIQBOT975P-BwmU22v5pN9d7iaGLaQih4TPkloclQ9ikWf4BaFMDU0NoCTxBrloN36HI0ocD7871Bj1_vfm6-N_cP335sbu8by5Wcm2EEGAcDVlhplHLKGemUoZJRLiQxZDAjsN4pIQ1tGemht1BxazmtV_Eb9OmUu8_p9wJl1pMvFkIwEdJSNKcdly1rKX0VZX19I-GciYp2J9TmVEqGUe-zn0x-1pTo41x6p89z6eNcR7nOVX0fzxXLMIH773rZpwJfTkB9Jxw8ZF2sh2jB-Qx21i75Vyr-AcPmrQA</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Bai, Jie</creator><creator>Zhang, Huijuan</creator><creator>Yang, Zhi</creator><creator>Li, Pinglan</creator><creator>Liu, Bin</creator><creator>Li, Dan</creator><creator>Liang, Shuang</creator><creator>Wang, Qimeng</creator><creator>Li, Zekun</creator><creator>Zhang, Jipeng</creator><creator>Chen, Shanan</creator><creator>Hou, Guohua</creator><creator>Li, Yuan</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>202212</creationdate><title>On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide</title><author>Bai, Jie ; Zhang, Huijuan ; Yang, Zhi ; Li, Pinglan ; Liu, Bin ; Li, Dan ; Liang, Shuang ; Wang, Qimeng ; Li, Zekun ; Zhang, Jipeng ; Chen, Shanan ; Hou, Guohua ; Li, Yuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-bfeefbaec6c8a99d9da8d9a18213680a0bafe27d968a14207e7ceaeccc31eae93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antidiabetic therapy</topic><topic>biocompatibility</topic><topic>biological rhythms</topic><topic>Blood Glucose</topic><topic>Blood glucose homeostasis</topic><topic>chronic diseases</topic><topic>closed loop systems</topic><topic>Concanavalin A</topic><topic>crosslinking</topic><topic>diabetes mellitus</topic><topic>Drug Carriers - chemistry</topic><topic>drugs</topic><topic>Exenatide</topic><topic>Glucose</topic><topic>Glucose-responsive delivery</topic><topic>half life</topic><topic>homeostasis</topic><topic>hyperglycemia</topic><topic>Hypoglycemic Agents</topic><topic>insulin</topic><topic>Nanogels</topic><topic>oxidation</topic><topic>Oxidized starch nanogels</topic><topic>peptides</topic><topic>Starch</topic><topic>therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Jie</creatorcontrib><creatorcontrib>Zhang, Huijuan</creatorcontrib><creatorcontrib>Yang, Zhi</creatorcontrib><creatorcontrib>Li, Pinglan</creatorcontrib><creatorcontrib>Liu, Bin</creatorcontrib><creatorcontrib>Li, Dan</creatorcontrib><creatorcontrib>Liang, Shuang</creatorcontrib><creatorcontrib>Wang, Qimeng</creatorcontrib><creatorcontrib>Li, Zekun</creatorcontrib><creatorcontrib>Zhang, Jipeng</creatorcontrib><creatorcontrib>Chen, Shanan</creatorcontrib><creatorcontrib>Hou, Guohua</creatorcontrib><creatorcontrib>Li, Yuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Jie</au><au>Zhang, Huijuan</au><au>Yang, Zhi</au><au>Li, Pinglan</au><au>Liu, Bin</au><au>Li, Dan</au><au>Liang, Shuang</au><au>Wang, Qimeng</au><au>Li, Zekun</au><au>Zhang, Jipeng</au><au>Chen, Shanan</au><au>Hou, Guohua</au><au>Li, Yuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2022-12</date><risdate>2022</risdate><volume>352</volume><spage>673</spage><epage>684</epage><pages>673-684</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Diabetes mellitus is a long-term chronic disease characterized by abnormal high level blood glucose (BG). An artificial closed-loop system that mimics pancreatic β-cells and releases insulin on demand has potential to improve the therapeutic efficiency of diabetes. Herein, a lectin Concanavalin A modified oxidized starch nanogel was designed to regulate glucose dynamically according to different glucose concentrations. The nanogels were formed by double cross-linking the Concanavalin A and glucose units on oxidized starch via specific binding and amide bonds to achieve the high drug loading and glucose responsiveness. The results showed that oxidized starch nanogels prolonged the half-life of antidiabetic peptide drug exenatide and released it in response to high BG concentrations. It could absorb BG at a high level and maintain glucose homeostasis. Besides, the oxidized starch nanogels performed well in recovering regular BG level from hyperglycemia state and maintaining in euglycemia state that fitted in a biological rhythm. In addition, the nanogels showed high biocompatibility in vivo and could improve plasma half-life and therapeutic efficacy of exenatide. Overall, the nanogels protected peptide drugs from degradation in plasma as a glucose-responsive platform showing a high potential for peptide drugs delivery and antidiabetic therapy. A lectin Concanavalin A (Con A) modified oxidized starch (OS) nanogels was developed through inverse-emulsion method by double cross-linking via Con A-glucose unit specific affinity binding and amide bonds between Con A and carboxyl groups on the TEMPO-oxidized starch. Peptide drug exenatide (EX) with extremely short half-life was effectively loaded into the nanogels due to its excellent swelling capacity. The EX-loaded nanogels showed a glucose-responsive controlled release property and could maintain glucose homeostasis. At low glucose concentration, the nanogels showed an interesting swelling and deswelling behavior as an “on-off” effect in response to adding glucose and removing glucose in the media. However, at high glucose concentration, glucose could competitively bind to Con A on nanogels, disrupting the nanogels and releasing the loaded EX to adjust the blood glucose level. The EX-loaded nanogels with a high biocompatibility showed a long-term therapeutic effect in diabetic mice. [Display omitted] •OS-Con A Ngels were prepared by double cross-linking via affinity and amide bonds.•OS-Con A Ngels showed a high biocompatibility and glucose stimuli-responsive property.•OS-Con A Ngels could responsively release EX and regulate glucose hemostasis.•The Ngels prolonged the half-life of EX and improved the glucose regulating property.•Ngels-EX showed both short and long-term therapeutic efficacy in diabetes mice.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36374646</pmid><doi>10.1016/j.jconrel.2022.10.039</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2022-12, Vol.352, p.673-684
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_3153842411
source MEDLINE; Elsevier ScienceDirect Journals
subjects Antidiabetic therapy
biocompatibility
biological rhythms
Blood Glucose
Blood glucose homeostasis
chronic diseases
closed loop systems
Concanavalin A
crosslinking
diabetes mellitus
Drug Carriers - chemistry
drugs
Exenatide
Glucose
Glucose-responsive delivery
half life
homeostasis
hyperglycemia
Hypoglycemic Agents
insulin
Nanogels
oxidation
Oxidized starch nanogels
peptides
Starch
therapeutics
title On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A48%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=On%20demand%20regulation%20of%20blood%20glucose%20level%20by%20biocompatible%20oxidized%20starch-Con%20A%20nanogels%20for%20glucose-responsive%20release%20of%20exenatide&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Bai,%20Jie&rft.date=2022-12&rft.volume=352&rft.spage=673&rft.epage=684&rft.pages=673-684&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2022.10.039&rft_dat=%3Cproquest_cross%3E2736303326%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2736303326&rft_id=info:pmid/36374646&rft_els_id=S0168365922007179&rfr_iscdi=true